Meet the Investigator

93 0
Dr. Michael Hayden
Dr. Michael Hayden

VITAL SIGNS

NAME: Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC CURRENT

Dr. Michael Hayden was recently appointed as the President of Global Research and Development and Chief Scientific Officer at Teva Pharmaceuticals. Dr. Hayden is the most highly cited author in Huntington disease. He is the founder and director of the Centre for Molecular Medicine and Therapeutics in Vancouver, and founder of three biotechnology companies (NeuroVir, Xenon Genetics, and Aspreva Pharmaceuticals).

POSITION: President of Global Research and Development and Chief Scientific Officer at Teva Pharmaceuticals

OTHER POSITIONS: Killam Professor of Medical Genetics at the University of British Columbia, Canada Research Chair in Human Genetics and Molecular Medicine, Founder and director for the Center for Molecular Medicine and Therapeutics in Vancouver, Canada, Program director of the Translational Laboratory in Genetic Medicine at the National University of Singapore, Founder of NeuroVir, Xenon Genetics, Inc., and Aspreva Pharmaceuticals, Inc

EDUCATION: MB, ChB, PhD, University of Cape Town, Post-doctoral fellowship, Harvard University

HOBBIES: Collecting art, photography, and enjoying creativity in other domains.

FAVORITE ARTIST: Ben Shahn, who was born in Lithuania and became a social activist in America. He is known for his works of social realism.

 

Related Post

HD Insights Volume 17 (PDF)

May 30, 2017 0
[pdf-embedder url=”http://huntingtonstudygroup.org/wp-content/uploads/2017/05/HD-Insights-Vol.-17-v.12-FINAL.pdf”] For a non-PDF version of HD Insights Vol. 17, click here.

Meet the Scientist : Beverly Davidson

May 30, 2017 0
VITAL SIGNS NAME: Beverly Davidson, PhD TITLE: Chief Scientific Strategy Officer at the Children’s Hospital of Philadelphia (CHOP); Director of…

Research Round-Up

May 30, 2017 0
By: Lise Munsie, PhD In neurons… The HD Induced Pluripotent Stem Cell (iPSC) consortium differentiated HD patient iPSCs into neuronal…